New data from a post hoc analysis of EXPAND study with siponimod (Mayzent, Novartis) in secondary progressive multiple sclerosis (MS) suggest that the drug may delay the need for a wheelchair. However ...

There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS) - a highly debilitating form of MS characterized by gradual, irreversible worsening of ...

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system where the affected individual’s immune system cells eradicate the myelin coating protecting its nerve fibers. The damage ...

AMSTERDAM — Siponimod significantly reduces the risk for confirmed disability progression (CDP) in patients with advanced secondary progressive multiple sclerosis (SPMS), results of a randomized trial ...

Doctor reading medical chart Investigators hypothesize siponimod will function as an alternative therapeutic choice to monoclonal antibodies in MS. SEATTLE — Prelaunch, neurologists believed that ...

Multiple Sclerosis Investigators believe the siponimod EXPAND study is the first trial of disease-modifying therapy to show superiority over a placebo for disability progression in SPMS. Siponimod ...

Results of a double-blind, randomized, phase 3 trial, published last week in The Lancet, show that siponimod—a selective sphingosine 1-phosphate receptor modulator—slowed the progression ...

US and European regulators have accepted filings for Novartis’s siponimod for secondary progressive multiple sclerosis (SPMS). The US Food and Drug Administration (FDA) and European Medicines Agency ...

Novartis is seeking approval on both sides of the Atlantic for use of experimental multiple sclerosis therapy siponimod to treat secondary progressive forms of the disease. Novartis is seeking ...

DORVAL, QC, March 3, 2020 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that Health Canada has approved Mayzent TM (siponimod) for the treatment of adults with ...

London, UK, January 20, 2020 – Novartis today announced that the European Medicines Agency (EMA) has granted a licence for the use of Mayzent ® (siponimod) for the treatment of adult patients with ...

Siponimod is an investigational, selective modulator of specific subtypes of the sphingosine-1-phosphate (S1P) receptor. Results from the Phase 3 EXPAND trial demonstrate that siponimod (BAF312; ...